Structure-based site of metabolism prediction for cytochrome P450 2D6. 2011

Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
Department of Chemistry, Katholieke Universiteit Leuven, Celestijnenlaan 200F, 3001 Heverlee, Belgium. moors@chem.kuleuven.be

Realistic representation of protein flexibility in biomolecular simulations remains an unsolved fundamental problem and is an active area of research. The high flexibility of the cytochrome P450 2D6 (CYP2D6) active site represents a challenge for accurate prediction of the preferred binding mode and site of metabolism (SOM) for compounds metabolized by this important enzyme. To account for this flexibility, we generated a large ensemble of unbiased CYP2D6 conformations, to which small molecule substrates were docked to predict their experimentally observed SOM. SOM predictivity was investigated as a function of the number of protein structures, the scoring function, the SOM-heme cutoff distance used to distinguish metabolic sites, and intrinsic reactivity. Good SOM predictions for CYP2D6 require information from the protein. A critical parameter is the distance between the heme iron and the candidate site of metabolism. The best predictions were achieved with cutoff distances consistent with the chemistry relevant to CYP2D6 metabolism. Combination of the new ensemble-based docking method with estimated intrinsic reactivities of substrate sites considerably improved the predictivity of the model. Testing on an independent set of substrates yielded area under curve values as high as 0.93, validating our new approach.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006418 Heme The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins. Ferroprotoporphyrin,Protoheme,Haem,Heme b,Protoheme IX
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D019389 Cytochrome P-450 CYP2D6 A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population. CYP2D6,Debrisoquine 4-Hydroxylase,Debrisoquine Hydroxylase,CYP 2D6,Cytochrome P450 2D6,Debrisoquine 4-Monooxygenase,Imipramine 2-Hydroxylase,Sparteine Monooxygenase,2-Hydroxylase, Imipramine,4-Hydroxylase, Debrisoquine,4-Monooxygenase, Debrisoquine,CYP2D6, Cytochrome P-450,Cytochrome P 450 CYP2D6,Debrisoquine 4 Hydroxylase,Debrisoquine 4 Monooxygenase,Hydroxylase, Debrisoquine,Imipramine 2 Hydroxylase,Monooxygenase, Sparteine,P-450 CYP2D6, Cytochrome,P450 2D6, Cytochrome
D020134 Catalytic Domain The region of an enzyme that interacts with its substrate to cause the enzymatic reaction. Active Site,Catalytic Core,Catalytic Region,Catalytic Site,Catalytic Subunit,Reactive Site,Active Sites,Catalytic Cores,Catalytic Domains,Catalytic Regions,Catalytic Sites,Catalytic Subunits,Core, Catalytic,Cores, Catalytic,Domain, Catalytic,Domains, Catalytic,Reactive Sites,Region, Catalytic,Regions, Catalytic,Site, Active,Site, Catalytic,Site, Reactive,Sites, Active,Sites, Catalytic,Sites, Reactive,Subunit, Catalytic,Subunits, Catalytic

Related Publications

Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
January 2012, ACS medicinal chemistry letters,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
January 2003, Current topics in medicinal chemistry,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
March 2006, The Journal of biological chemistry,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
July 2009, Pharmacogenetics and genomics,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
March 2006, Archives of biochemistry and biophysics,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
November 2018, ChemMedChem,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
March 2010, Journal of computer-aided molecular design,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
May 2010, Journal of computer-aided molecular design,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
August 2011, Clinical pharmacokinetics,
Samuel L C Moors, and Ann M Vos, and Maxwell D Cummings, and Herman Van Vlijmen, and Arnout Ceulemans
January 2007, Current drug metabolism,
Copied contents to your clipboard!